Article
Biochemistry & Molecular Biology
Tao Ming Sim, Siying Jane Ong, Anselm Mak, Sen Hee Tay
Summary: This review discusses the bench to bedside translation of the type I IFN pathway and explores some unresolved issues when selecting SLE patients for treatment with biologics targeting type I IFNs.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Immunology
Chiara Kirchler, Emma Husar-Memmer, Klemens Rappersberger, Kylie Thaler, Ruth Fritsch-Stork
Summary: The study systematically reviewed the role of interferon I and fibroblast growth factor-23 in cardiovascular diseases in patients with SLE or CLE, finding an association between IFN-I and MACE, with the strongest association found for cardiac events. However, the results of the studies showed some inconsistency and bias, and there is a lack of research on CLE and FGF-23.
AUTOIMMUNITY REVIEWS
(2021)
Article
Rheumatology
Kerry A. Casey, Michael A. Smith, Dominic Sinibaldi, Nickie L. Seto, Martin P. Playford, Xinghao Wang, Philip M. Carlucci, Liangwei Wang, Gabor Illei, Binbing Yu, Shiliang Wang, Alan T. Remaley, Nehal N. Mehta, Mariana J. Kaplan, Wendy White
Summary: The study suggests that blocking the type I IFN receptor with anifrolumab can significantly reduce NET formation, improve cardiometabolic disease markers, and outperform placebo.
ARTHRITIS & RHEUMATOLOGY
(2021)
Article
Multidisciplinary Sciences
Josephine Brown, Georges Abboud, Longhuan Ma, Seung-Chul Choi, Nathalie Kanda, Leilani Zeumer-Spataro, Jean Lee, Weidan Peng, Joy Cagmat, Tamas Faludi, Mansour Mohamadzadeh, Timothy Garrett, Laura Mandik-Nayak, Alexander Chervonsky, Andras Perl, Laurence Morel
Summary: A skewed tryptophan metabolism was found in lupus, and the study discovered that both microbial and T cell intrinsic factors contribute to the production of tryptophan metabolites that enhance inflammatory phenotypes in lupus T cells.
Article
Immunology
Shifei Li, Qijun Wu, Zhuyan Jiang, Yaguang Wu, Yuhong Li, Bing Ni, Jun Xiao, Zhifang Zhai
Summary: The study found that miR-31-5p may be involved in the pathogenesis of SLE by negatively regulating SLC15A4, thereby increasing the levels of IFN-alpha and ISGs in pDCs.
JOURNAL OF INFLAMMATION RESEARCH
(2022)
Editorial Material
Cell Biology
Simon Fillatreau
Summary: The study reveals that autoantibodies in systemic lupus erythematosus (SLE) can have a protective role by neutralizing type I interferons (IFNs) and restraining the activation of pathogenic B cells.
CELL REPORTS MEDICINE
(2023)
Article
Immunology
Kanwal Zahid Siddiqi, Amanda Hempel Zinglersen, Katrine Kjaer Iversen, Niclas Stefan Rasmussen, Christoffer Tandrup Nielsen, Soren Jacobsen
Summary: This study establishes an IFN signature based on the expression of IRGs in SLE patients and identifies an association between a type II IRG subset and disease activity. These findings have significant implications for selecting clinically relevant IFN signatures.
JOURNAL OF AUTOIMMUNITY
(2022)
Article
Multidisciplinary Sciences
Norzawani Buang, Lunnathaya Tapeng, Victor Gray, Alessandro Sardini, Chad Whilding, Liz Lightstone, Thomas D. Cairns, Matthew C. Pickering, Jacques Behmoaras, Guang Sheng Ling, Marina Botto
Summary: This study reveals that high expression of type I interferon in SLE patients affects mitochondrial function and cell metabolism in CD8(+) T cells, leading to cell death. Furthermore, these abnormalities can be corrected by NAD+ supplementation.
NATURE COMMUNICATIONS
(2021)
Review
Biochemistry & Molecular Biology
Madhu Ramaswamy, Raj Tummala, Katie Streicher, Andre Nogueira da Costa, Philip Z. Brohawn
Summary: Systemic lupus erythematosus (SLE) presents a challenging treatment landscape due to its multifaceted etiology and complex immunopathogenesis. While targeting the B-cell pathway has limitations, recent approval of anifrolumab, a type I interferon-blocking antibody, highlights the therapeutic potential of targeting the dysregulated interferon pathway in SLE patients. Further research into the pleiotropic biology of interferons and their intersection with SLE disease pathology will be crucial for the development of effective targeted therapies.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Review
Pharmacology & Pharmacy
Sebastian Bruera, Thandiwe Chavula, Riya Madan, Sandeep. K. K. Agarwal
Summary: Systemic lupus erythematosus (SLE) is a complex autoimmune disease with diverse clinical manifestations. Recent studies have highlighted the important role of the type I interferon (IFN) pathway in SLE pathogenesis. Therapeutic strategies targeting type I IFN and related pathways are being developed for the treatment of SLE. This review discusses the role of type I IFN in SLE pathogenesis and its potential as a biomarker and therapeutic target for SLE patients.
FRONTIERS IN PHARMACOLOGY
(2023)
Review
Biochemistry & Molecular Biology
Stefania Gallucci, Sowmya Meka, Ana M. Gamero
Summary: Type I interferons (IFNs) play a crucial role in the pathogenesis of Systemic Lupus Erythematosus (SLE), and aberrant IFN signaling can exacerbate SLE. Genetic and epigenetic abnormalities are present in SLE patients. Neutralizing anti-type I IFN receptor antibodies may be a therapeutic strategy.
Review
Immunology
Zhihui Liu, Ruijuan Cheng, Yi Liu
Summary: This study evaluated the safety of anifrolumab in patients with moderate to severe systemic lupus erythematosus (SLE). The results showed that serious adverse events were less common in the anifrolumab group compared to the placebo group. The most common adverse events included upper respiratory tract infection, nasopharyngitis, bronchitis, and herpes zoster. Anifrolumab is considered a well-tolerated option for the treatment of SLE patients with good safety.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Rheumatology
Taro Iwamoto, Jessica M. Dorschner, Shanmugapriya Selvaraj, Valeria Mezzano, Mark A. Jensen, Danielle Vsetecka, Shreyasee Amin, Ashima Makol, Thomas Osborn, Kevin Moder, Vaidehi R. Chowdhary, Peter Izmirly, H. Michael Belmont, Robert M. Clancy, Jill P. Buyon, Ming Wu, Cynthia A. Loomis, Timothy B. Niewold
Summary: This study found an association between high serum IFN and subtypes of lupus nephritis, and investigated the effect of IFN on renal tissues and cells.
JOURNAL OF RHEUMATOLOGY
(2022)
Article
Immunology
Yushiro Endo, Tomohiro Koga, Hiroki Otaki, Kaori Furukawa, Atsushi Kawakami
Summary: In this study, a patient with systemic lupus erythematosus carrying a heterozygous p.Asp130Asn mutation in the TREX1 gene was identified, leading to elevated serum interferon levels and abnormal expression of IFN signature genes. Molecular dynamics simulation showed that this mutation caused significant changes in the active site of the TREX1 protein.
CLINICAL IMMUNOLOGY
(2021)
Article
Immunology
Mengjia Shen, Congcong Duan, Changhao Xie, Hongtao Wang, Zhijun Li, Baiqing Li, Tao Wang
Summary: This study identified differentially expressed ISGs in the PBMCs of SLE patients and healthy individuals, including NRIR, RSAD2, USP18, IFI44, and ISG15. These findings may contribute to future diagnosis and new personalized targeted therapies for SLE.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Rheumatology
Guoli Sun, Adelina Yafasova, Charlotte Andersson, John J. McMurray, Pardeep S. Jhund, Kieran F. Docherty, Mikkel Faurschou, Christoffer T. Nielsen, Morten Schou, Gunnar H. Gislason, Christian Torp-Pedersen, Emil L. Fosbol, Lars Kober, Jawad H. Butt
Summary: SSc is associated with higher rates of heart failure and other adverse cardiovascular outcomes, regardless of gender and age. Patients with new-onset HF and a history of SSc have a higher mortality rate.
Review
Rheumatology
Srijana Davuluri, Christian Lood, Lorinda Chung
Summary: This study aims to provide updated information on the prevalence, pathogenesis, diagnostics, and therapeutics of calcinosis cutis associated with systemic sclerosis. Recent findings show ethnic and geographical differences in the prevalence of calcinosis, and long-term use of proton pump inhibitors may increase the risk. Few observational studies have shown mild benefit with minocycline and topical sodium thiosulfate. Surgical treatment remains the most effective therapy.
CURRENT OPINION IN RHEUMATOLOGY
(2022)
Article
Immunology
Kanwal Zahid Siddiqi, Amanda Hempel Zinglersen, Katrine Kjaer Iversen, Niclas Stefan Rasmussen, Christoffer Tandrup Nielsen, Soren Jacobsen
Summary: This study establishes an IFN signature based on the expression of IRGs in SLE patients and identifies an association between a type II IRG subset and disease activity. These findings have significant implications for selecting clinically relevant IFN signatures.
JOURNAL OF AUTOIMMUNITY
(2022)
Review
Rheumatology
Yann L. C. Becker, Bhargavi Duvvuri, Paul R. Fortin, Christian Lood, Eric Boilard
Summary: Mitochondria play crucial roles in rheumatic diseases, and understanding their functions and dysfunctions can lead to novel therapeutic strategies.
NATURE REVIEWS RHEUMATOLOGY
(2022)
Article
Rheumatology
Despina Michailidou, Linda Johansson, Runa Kuley, Ting Wang, Payton Hermanson, Solbritt Rantapaa-Dahlqvist, Christian Lood
Summary: The study aimed to evaluate the increased levels of neutrophil activation markers in PMR patients. The results showed that calprotectin and neutrophil extracellular traps (NETs) were elevated in PMR patients, and neutrophil activation was associated with immune complexes and Fc gamma RIIA. The levels of immune complexes correlated with the expression of CD66b and CD11b, and decreased after glucocorticoid therapy. Calprotectin can be used as a biomarker for treatment response in PMR patients.
Article
Rheumatology
Richard E. Moore, Ting Wang, Bhargavi Duvvuri, Marie L. Feser, Kevin D. Deane, Joshua J. Solomon, J. Lee Nelson, M. Kristen Demoruelle, Christian Lood
Summary: This study investigated the presence and significance of antimitochondrial antibodies (AMAs) in patients with rheumatoid arthritis (RA). The results showed that AMA levels were elevated in RA patients and associated with disease severity and progression.
ARTHRITIS & RHEUMATOLOGY
(2023)
Editorial Material
Rheumatology
Lesley Ann Saketkoo, Antonia Valenzuela, Susan Kim, Liza J. McCann, Christian Lood, Dawn M. Wahezi, Victoria P. Werth, Belina Yi, Helene Alexanderson, Susan Maillard, Clarissa Pilkington, Kim Fligelstone, Barbara Limbach, Amir B. Orandi, Malin Regardt, Anne-Marie Russell, Srijana Davuluri, Ingrid deGroot, Floranne Ernste, Julie J. Paik, Carlos A. von Muhlen, Mazen M. Dimachkie, Pedro M. Machado, Elie Naddaf, Barbara M. Shafranski, Latika Gupta, Francesco Zulian, Lorinda Chung
Letter
Rheumatology
Richard Moore, Ting Wang, Marina Barguil Macedo, Christian Lood
ARTHRITIS & RHEUMATOLOGY
(2023)
Article
Rheumatology
A. I. Khadjinova, X. Wang, A. Laine, K. Ukadike, M. Eckert, A. Stevens, A. A. Bengtsson, C. Lood, T. Mustelin
Summary: This study found that patients with systemic lupus erythematosus (SLE) express HERV-K proviruses and that the encoded Env protein of this virus can elicit an immune response in patients, particularly during active disease.
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY
(2022)
Meeting Abstract
Rheumatology
Bhargavi Duvvuri, Lauren Pachman, Gabrielle Morgan, Payton Hermanson, Ting Wang, Christian Lood
ARTHRITIS & RHEUMATOLOGY
(2022)
Meeting Abstract
Rheumatology
Despina Michailidou, Bhargavi Duvvuri, Runa Kuley, David Cuthbertson, Peter Grayson, Nader Khalidi, Curry Koening, Carol Langford, Carol McAlear, Larry Moreland, Christian Pagnoux, Philip Seo, Ulrich Specks, Antoine Sreih, Kenneth J. Warrington, Tomas Mustelin, Paul Monach, Peter Merkel, Christian Lood
ARTHRITIS & RHEUMATOLOGY
(2022)
Meeting Abstract
Rheumatology
Despina Michailidou, Linda Johansson, Runa Kuley, Ting Wang, Payton Hermanson, Solbritt Rantapaa-Dahlqvist, Christian Lood
ARTHRITIS & RHEUMATOLOGY
(2022)
Meeting Abstract
Rheumatology
Yann Becker, Eric Boilard, Emmanuelle Rollet-Labelle, Christian Lood, Anne-Sophie Julien, Joannie Leclerc, Tania Levesque, Murray Urowitz, John Hanly, Caroline Gordon, Sang-Cheol Bae, Juanita Romero-Diaz, Jorge Sanchez-Guerrero, Ann E. Clarke, Sasha Bernatsky, Daniel Wallace, David Isenberg, Anisur Rahman, Joan Merrill, Dafna Gladman, Ian N. Bruce, Michelle Petri, Ellen M. Ginzler, Mary Anne Dooley, Rosalind Ramsey-Goldman, Susan Manzi, Andreas Jonsen, Graciela Alarcon, Ronald Van Vollenhoven, Cynthia Aranow, Guillermo Ruiz-Irastorza, S. Sam Lim, Murat Inanc, Kenneth Kalunian, Soren Jacobsen, Christine Peschken, Diane Kamen, Anca Askanase, Jill Buyon, Paul R. Fortin
ARTHRITIS & RHEUMATOLOGY
(2022)
Meeting Abstract
Rheumatology
Srijana Davuluri, Urvashi Kaundal, Christian Lood, Puneet Kapoor, Yumeko Kawano, Stefania Dell'Orso, Zuoming Deng, Zsuzsanna McMahan, Ami Shah, Laura Hummers, Daniel Kastner, Fredrick Wigley, David Fiorentino, Pravitt Gourh, Lorinda Chung
ARTHRITIS & RHEUMATOLOGY
(2022)
Article
Rheumatology
N. S. Rasmussen, A. H. Draborg, G. Houen, C. T. Nielsen
Summary: This study found that circulating microvesicles expressing G3BP are associated with ongoing/recently active cytomegalovirus infection in systemic lupus erythematosus patients, suggesting a potential link between specific viral infections and pathogenic microvesicles in SLE.
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY
(2022)
